» Articles » PMID: 20565332

Timelines in the Diagnostic Evaluation of People with Suspected Amyotrophic Lateral Sclerosis (ALS)/motor Neuron Disease (MND)--a 20-year Review: Can We Do Better?

Overview
Publisher Informa Healthcare
Specialty Neurology
Date 2010 Jun 23
PMID 20565332
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

This paper examines diagnostic timelines for people suspected of having ALS/MND over a 20-year period, evaluates the impact of a 'fast track' diagnostic process and discusses typical causes of diagnostic delay. Key diagnostic timelines (dates of first symptom, diagnosis and death) were reviewed for people diagnosed between 1989 and 2008. Patients evaluated through a fast-track diagnostic process and those investigated through traditional neurology clinics were compared. Typical causes of diagnostic delay were investigated. Results showed that diagnostic timelines have been surprisingly consistent over this 20-year period. Time from first symptom to diagnosis hovered around 12 months, with the diagnosis typically being made around the midpoint (50% of total disease duration elapsed) of the disease pathway. The introduction of a fast-track process has not to date affected overall performance but has shortened times from referral to diagnosis. Diagnostic delays appear to be associated with clinical complexity and delays in referral, both within primary and secondary care services. In conclusion, more widespread implementation of fast-track processes could potentially reduce diagnostic delays. Educational interventions among health care professionals both in primary and secondary care may also help shorten diagnostic pathways.

Citing Articles

Genetic testing for monogenic forms of motor neuron disease/amyotrophic lateral sclerosis in unaffected family members.

Howard J, Chaouch A, Douglas A, MacLeod R, Roggenbuck J, McNeill A Eur J Hum Genet. 2024; 33(1):7-13.

PMID: 39501102 PMC: 11711763. DOI: 10.1038/s41431-024-01718-4.


Blood diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis.

Lv Y, Li H Neural Regen Res. 2024; 20(9):2556-2570.

PMID: 39314138 PMC: 11801290. DOI: 10.4103/NRR.NRR-D-24-00286.


Intermuscular coherence as an early biomarker for amyotrophic lateral sclerosis: The protocol for a prospective, multicenter study.

Issa N, Aydin S, Polley E, Carberry N, Garret M, Smith S PLoS One. 2024; 19(5):e0303053.

PMID: 38776297 PMC: 11111088. DOI: 10.1371/journal.pone.0303053.


Medication use and risk of amyotrophic lateral sclerosis: using machine learning for an exposome-wide screen of a large clinical database.

Rotem R, Bellavia A, Paganoni S, Weisskopf M Amyotroph Lateral Scler Frontotemporal Degener. 2024; 25(3-4):367-375.

PMID: 38426489 PMC: 11075178. DOI: 10.1080/21678421.2024.2320878.


The complexity of multidisciplinary respiratory care in amyotrophic lateral sclerosis.

Berlowitz D, Mathers S, Hutchinson K, Hogden A, Carey K, Graco M Breathe (Sheff). 2023; 19(3):220269.

PMID: 37830099 PMC: 10567075. DOI: 10.1183/20734735.0269-2022.